Carbon Accounting for Pharmaceutical Companies in India

India's pharmaceutical sector is a global powerhouse, producing everything from active pharmaceutical ingredients (APIs) to finished formulations. Yet this success comes with significant environmental responsibility. As India's top pharma companies face mounting pressure from investors, regulators, and consumers, accurate carbon accounting has become essential. BRSR compliance, evolving stakeholder expectations, and the complexity of global supply chains make understanding your emissions landscape critical.

Pharmaceutical Emissions Overview and Scope Breakdown

Pharmaceutical manufacturing is energy and resource-intensive. Understanding your emissions across all three scopes is the foundation of credible carbon accounting.

Scope 1 Emissions in Pharma Manufacturing

Scope 1 direct emissions come from assets you own or control. For Indian pharma companies, these include:

• Steam boilers powering API synthesis and drying processes
• Solvent use in chemical synthesis and extraction (volatile organic compounds)
• On-site fuel combustion for heat and power backup
• Process emissions from chemical reactions themselves

Many Indian pharma facilities operate continuous batch processes that rely heavily on steam. The energy intensity of these operations often exceeds other manufacturing sectors. If your facility produces APIs like antibiotics or hormones, your Scope 1 emissions can be substantial.

Scope 2 Electricity Emissions

Scope 2 covers purchased electricity. Pharma facilities demand exceptional energy because of:

• Clean rooms and controlled environment chambers (maintained at specific temperature and humidity)
• High-speed centrifuges and filtration systems
• Laboratory analytical equipment running 24/7
• HVAC systems ensuring ISO Class 5 to Class 8 compliance

India's electricity grid remains carbon-intensive, with coal still dominant in many regions. This means Scope 2 emissions are often the largest component for Indian pharma companies. Grid-linked emissions vary significantly by state - facilities in Andhra Pradesh or Maharashtra may have different emission factors than those in Kerala or Punjab.

Scope 3 Supply Chain Complexity

Scope 3 indirect emissions encompass your entire value chain. For pharma companies, this includes:

• API procurement (often from China, Russia, or other API manufacturers)
• Raw material sourcing (solvents, excipients, packaging)
• Third-party contract manufacturing
• Finished product distribution and cold chain logistics
• Employee commuting and business travel
• Waste disposal and chemical processing

Learn more about Scope 1, 2 and 3 Emissions in India.

Cold Chain and Refrigerant Emissions: A Pharma-Specific Challenge

Refrigeration and controlled storage are non-negotiable for pharmaceutical products. Yet refrigerants present a significant carbon footprint.

Refrigerant Leakage and HFC/HCFC Emissions

Many Indian pharma facilities still use older refrigerants. Hydrofluorocarbons (HFCs) and hydrochlorofluorocarbons (HFCs) have high global warming potentials. Even small leaks from cold storage units, walk-in coolers, and transport containers compound across your facility.

Cold Chain Logistics

Products requiring 2-8°C storage must maintain temperature controls from warehouse to customer. This includes:

• Refrigerated transport vehicles (high fuel consumption)
• Cold storage facility operations
• Insulation and temperature monitoring systems

For companies distributing across India's diverse geography - from coastal regions to high-altitude areas - cold chain energy costs and emissions are substantial.

BRSR Requirements for Indian Pharmaceutical Companies

The Business Responsibility and Sustainability Reporting (BRSR) framework is mandatory for the top 1,000 listed companies by market capitalization. Most large Indian pharma companies fall within this scope.

Water Disclosure and Environmental Metrics

BRSR Principle 6 requires disclosure of:

• Total water consumption (megaliters)
• Water recycling and reuse rates
• Wastewater treatment and discharge quality
• Water stress assessment for facility locations

Pharmaceutical manufacturing is water-intensive. API production, cleaning of equipment, and cooling systems consume significant volumes. BRSR asks you to quantify this and explain your water management strategy.

Chemical Emissions and Hazardous Waste

You must disclose:

• Hazardous waste generated and safely disposed
• Emissions to air, water, and land from manufacturing processes
• Chemical inventory and handling protocols
• Worker safety incidents related to chemical exposure

BRSR expects transparency. If your facility generates pharmaceutical waste or chemical residues, these must be quantified, categorized, and disclosed with management approaches.

Explore What is BRSR Reporting? for comprehensive compliance guidance.

Scope 3 Challenges: Navigating Pharma Supply Chain Complexity

Scope 3 emissions are notoriously difficult to measure and reduce in pharma, yet BRSR increasingly demands this data.

API Sourcing and Geographic Risk

Most Indian pharma companies source APIs globally. China supplies approximately 50% of APIs to Indian manufacturers. Tracing emissions from Chinese API facilities involves:

• Requesting supplier-level data (often unavailable)
• Using industry averages and emission factors
• Estimating transportation by sea, rail, and truck

This indirect sourcing makes Scope 3 assessment resource-intensive. Without supplier engagement, emissions remain estimated rather than actual.

Contract Manufacturing and Third-Party Complexity

Many Indian companies outsource manufacturing to contract manufacturers across India and internationally. Each third-party facility adds complexity to your footprint accounting. You must identify all contract manufacturers, obtain their energy and waste data, and allocate emissions appropriately.

FAQ

What are the main sources of Scope 1 emissions for Indian pharma manufacturers?

Steam boilers, solvent use in API synthesis, and on-site fuel combustion for heat and backup power are the primary Scope 1 sources. Process emissions from chemical reactions also contribute significantly, particularly in API and fermentation-based manufacturing.

How can Indian pharma companies reduce their Scope 2 emissions?

Transitioning to renewable energy through rooftop solar installations or renewable energy credits (RECs), upgrading to high-efficiency HVAC systems, LED lighting retrofits, and facility-level energy audits are proven strategies. Many Indian pharma companies have set net-zero targets leveraging wind and solar power in renewable-rich states.

Is Scope 3 reporting mandatory under BRSR for pharmaceutical companies?

BRSR requires disclosure of material Scope 3 categories. For pharma companies, supply chain emissions, distribution, and waste disposal are considered material. While you must disclose your approach, some companies use screening and prioritization methods rather than comprehensive Scope 3 quantification initially.

When should Indian pharma companies begin Scope 3 supplier engagement?

Immediately, ideally. BRSR compliance timelines and investor expectations mean supplier data collection should start now. Begin with your largest API suppliers and contract manufacturers, establishing data-sharing protocols and emission calculation methodologies.

What role does cold chain refrigeration play in pharma carbon accounting?

Cold chain operations account for 10-20% of total emissions for companies with temperature-sensitive products. Refrigerant leakage (HFCs, HCFCs), transport fuel, and facility cooling contribute significantly. Upgrading to low-GWP refrigerants and optimizing logistics reduces both emissions and costs.

Conclusion

Carbon accounting for Indian pharmaceutical companies demands a comprehensive approach spanning manufacturing operations, supply chain visibility, and regulatory compliance. BRSR mandates transparency on emissions, water use, and chemical management - making robust data collection essential.

Your Scope 1 and 2 emissions are largely controllable through facility-level investments in energy efficiency, renewable energy, and process optimization. Scope 3 remains challenging but increasingly critical to investors and regulators.

Platforms like Greenio help Indian pharma companies automate emissions calculation, manage BRSR compliance, and track progress toward sustainability targets. Starting with a detailed baseline assessment across all three scopes positions your company for credible reporting and strategic decarbonization.